MOH Molina Healthcare Inc Common Stock

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Select Strategy”. A copy of the letter can be downloaded here. The Strategy delivered 5.08% (net of fees) in the quarter, while the Russell 3000 Index returned 15.44%, supported by AI-driven investment, strong corporate earnings, and easing geopolitical concerns. […]

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Oscar Health's profit rebound faces a test as rising medical spending and a larger member base threaten second-half profitability.

Molina Healthcare's Medicaid recovery, Medicare duals growth and contract wins support a focused turnaround story, positioning it ahead of UnitedHealth.

Molina told investors in February that a Medicare drug plan serving tens of thousands of members would cease to exist. The members found out in October. Here is what that eight-month silence means for anyone still holding that plan card.

Centene's robust cash flow is helping cut debt, with a lower debt-to-capital ratio and added liquidity reshaping its balance sheet.

Molina Healthcare (MOH) drew fresh attention after recent trading left the stock around $197.80, with returns down 1.5% on the day and roughly 7.6% over the past week. That pullback comes after a year where Molina Healthcare’s share price return is up 10.8% year to date, yet the 1 year total shareholder return is a more modest 8.8% and the 3 year total shareholder return shows a 42.1% decline, which suggests that recent momentum is rebuilding from a weaker long term base. See how Molina...

Kopernik Global Investors recently released its “Global All-Cap Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund faced a difficult investment environment in the second quarter of 2026, as momentum-driven markets and soaring semiconductor stocks sharply favored growth-oriented equities over the fund’s value-focused approach. Class I shares declined 6.60% […]

Burry Pulls the Trigger on Nvidia and Palantir Put Options as Market Risks Rise

Burry remains short Nvidia and Palantir and still holds 2027 puts on Palantir and QQQ.

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including Molina Healthcare (NYSE:MOH) and its peers.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 25.1% over the past six months, topping the S&P 500 by 13.1 percentage points.

Oscar Health's membership jumps 46% to 2.96 million, but seasonal enrollment and medical utilization keep profitability in focus.

Oscar Health has surged 109% YTD as membership, revenue and expansion plans strengthen, though its price-to-book multiple tops the industry average.

The AI rally put Burry’s bearish stance under pressure as Palantir, CoreWeave, Oracle, Micron, Tesla, Nebius and Nvidia all climbed during August.

Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MOH's contract wins, acquisitions and cash generation support growth, but elevated medical costs and valuation pose risks.

Molina Healthcare event puts focus on growth, profitability mix Molina Healthcare (MOH) drew fresh attention after a recent screen highlighted its 7.3% annual revenue growth alongside a reported net loss, prompting investors to reassess how its scale in Medicaid and Medicare shapes the stock’s risk reward profile. Molina Healthcare’s share price has gained 12.2% over the past 90 days and 11.9% year to date, while the 1 year total shareholder return of 14.2% contrasts with weaker 3 and 5 year...

Molina Healthcare stock presents an interesting setup for valuation focused investors, with a 38.1% share price decline over the past three years sitting alongside a high value score and an undervalued read on market multiples. The share price is down 38.1% over the past three years, which raises the question of whether recent weakness has already priced in many of the concerns around the business. Stronger confidence in long term Medicaid funding can support higher earnings expectations for...

UnitedHealth, The Cigna, Humana, Centene and Molina have been highlighted in this Industry Outlook article.

An aging U.S. population, digital transformation, a diversified membership mix and strategic M&A are likely to drive the performance of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.

LULU shares have fallen more than 40% this year, leaving the stock well below its recent highs.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sycamore Capital Management, a franchise of Victory Capital Management, released its Q2 2026 investor letter for “Sycamore Mid Cap Value Equity Strategy”. A copy of the letter can be downloaded here. Sycamore Capital’s Mid Cap Value investment team focuses on a bottom-up approach to identify undervalued businesses with growth potential. In Q2 2026, the strategy […]

Burry Bets on Molina Healthcare's Long-Term Future Despite Near-Term Pressure

The investor made famous by The Big Short is doubling down on his bets against some of the biggest names in AI.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

The “Big Short” investor is betting against AI-linked names while adding to his position in Molina Healthcare.

Older adults could be scrambling for new health coverage next year, especially in rural markets that have fewer insurance choices.

UNH's improving cost control, lower medical costs and higher 2026 outlook are boosting confidence as its profitability recovery gains traction.

S&P 500 health insurer Centene blew away Q2 earnings forecasts amid lower-than-expected Affordable Care Act Marketplace benefit costs. Oscar Health, a pure play on the ACA, flashed an early entry buy signal amid Centene's good news and a big price target hike.

Molina Healthcare (NYSE:MOH) plans to significantly scale back its Affordable Care Act business from 2027. The company intends to limit ACA operations to six states and reduce premiums by a meaningful margin. The move follows ongoing pressure on ACA profitability, including falling membership and higher medical costs. Molina Healthcare, trading at $197.55, is restructuring its portfolio as it responds to challenges in the ACA segment. The stock is up 10.7% year to date and 19.7% over the...

HUM enters Q2 earnings with strong premium and membership growth expectations, but rising medical costs and expenses could test its bottom line.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Molina Healthcare (NYSE:MOH) reported second-quarter 2026 adjusted earnings per share of $1.51 on $10.2 billion of premium revenue, with management pointing to steady Medicaid performance and stronger-than-expected Medicare duals results while acknowledging continued pressure in its Marketplace busi

Molina Healthcare Inc (MOH) reports robust earnings and revenue growth, but faces hurdles in its Marketplace segment and regulatory pressures.

Molina beats Q2 earnings estimates as lower operating expenses offset weaker premium revenues, declining membership and softer investment income, while the company raises its 2026 earnings guidance.

Moby summary of Molina Healthcare, Inc.'s Q2 2026 earnings call

Molina’s second quarter was complicated, with stability in Medicaid and outperformance in Medicare Advantage overshadowed by problems in the ACA exchanges. The trend was “unfortunate,” according to the insurer’s CEO.

Molina Healthcare (NYSE:MOH) shares dropped more than 9% in premarket trading on Thursday after the health insurer issued a full-year revenue outlook that disappointed investors, despite reporting second-quarter earnings ahead of market expectations. While profitability exceeded forecasts, concerns over slowing revenue growth and ongoing Medicaid headwinds weighed heavily on market sentiment.

Molina healthcare has seen its stock edge down in recent days amid concerns about Medicaid cost pressures.

The headline numbers for Molina (MOH) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

By Padmanabhan Ananthan July 22 (Reuters) - Molina Healthcare raised its annual profit forecast on Wednesday after posting second-quarter profit and revenue that beat Wall Street estimates, helped by

Molina (MOH) delivered earnings and revenue surprises of +10.22% and -0.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The insurance company, which primarily operates through Medicare and Medicaid, said net income fell to $60 million due to lower premium revenue and an increase in the medical care ratio.

Healthcare insurance company Molina Healthcare (NYSE:MOH) met Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 4.8% year on year to $10.87 billion. On the other hand, the company’s full-year revenue guidance of $42 billion at the midpoint came in 5.1% below analysts’ estimates. Its non-GAAP profit of $1.51 per share was 7.8% above analysts’ consensus estimates.

CNC reports Q2 results July 28 as investors weigh improving profitability against membership declines and revenue pressure ahead of earnings.

Molina healthcare has seen its stock edge down in recent days amid concerns about Medicaid cost pressures.